ITF Pharma Inc. voluntarily recalled Tiglutik (riluzole) Oral Suspension due to failed viscosity specifications, the FDA said on Oct. 20, 2023. The Class II recall involves 1,792 bottles distributed to a Tennessee distributor.
How to tell if you have it
- Brand: ITF Pharma
- Product: Tiglutik (riluzole) Oral Suspension 50 mg/10 mL (5 mg/mL), 600 mL
- NDC: 70726-0303-1 (carton) and 70726-0303-2 (bottle)
- Lot codes: 2231901, Exp. 11/30/2025; 2307901, Exp. 03/31/2026
The hazard
The recall was initiated because the product failed viscosity specifications, resulting in out-of-specification test results. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show other recent recalls of similar products include Sun Pharmaceutical Fluocinonide Cream Recall (2026-03-25) and Sun Pharmaceutical Diclofenac Gel Recall (2026-01-27). Somerset Therapeutics Cisatracurium Besylate Injection Recall occurred on 2025-11-26.